Literature DB >> 28618892

Cutaneous lupus erythematosus and the risk of deep venous thrombosis and pulmonary embolism: A Danish nationwide cohort study.

O Ahlehoff1, J J Wu2, J Raunsø3, S L Kristensen3, U Khalid3, K Kofoed4, G Gislason3.   

Abstract

Background Venous thromboembolism (VTE) is a major public health concern. Lupus erythematosus (LE) is a chronic autoimmune disease ranging from localized cutaneous disease (CLE) to systemic involvement (SLE). Patients with SLE have an increased risk of venous thromboembolism (VTE), but little is known about the CLE-related risk of VTE. Methods To evaluate the risk of VTE in patients with SLE and CLE as compared to the general population, a retrospective cohort study was conducted. Incidence rates and hazard ratios (HRs) with 95% confidence intervals (CIs) from multivariable Cox regression models were used to evaluate and compare the risk of VTE. Registries of hospitalizations, outpatient visits, and prescription drug use were studied to determine the risk of VTE in patients with CLE and SLE and the general population between 1997 and 2011. Results A total of 3234 patients with CLE and 3627 patients with SLE were identified and compared to 5,590,070 individuals in the reference population. The incidence rates per 1000 year of VTE were higher in patients with LE, i.e. 1.20, 3.06, and 5.24 for the reference population, CLE, and SLE, respectively. In adjusted models, both CLE (HR 1.39; 95% CI 1.10-1.78) and SLE (HR 3.32; 95% CI 2.73-4.03) were associated with a statistically significant increased risk of VTE, compared to the reference population. Conclusion In this nationwide study, both CLE and SLE were significant risk factors for VTE. The results add to our understanding of comorbidities in patients with LE, and call for further studies and increased awareness of thromboembolic complications in patients with CLE.

Entities:  

Keywords:  Lupus erythematosus; epidemiology; venous thromboembolism

Mesh:

Year:  2017        PMID: 28618892     DOI: 10.1177/0961203317716306

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  10 in total

Review 1.  Cutaneous lupus erythematosus and cardiovascular disease: current knowledge and insights into pathogenesis.

Authors:  Lisa N Guo; Vinod E Nambudiri
Journal:  Clin Rheumatol       Date:  2020-07-05       Impact factor: 2.980

2.  Long-term risk of adverse cardiovascular outcomes associated with cutaneous lupus erythematosus: a nationwide cohort study.

Authors:  Abdulrahman N Shams-Eldin; Adelina Yafasova; Mikkel Faurschou; Morten Schou; Guoli Sun; Gunnar H Gislason; Christian Torp-Pedersen; Emil L Fosbøl; Lars Køber; Jawad H Butt
Journal:  Clin Rheumatol       Date:  2022-07-30       Impact factor: 3.650

Review 3.  Management of Chronic Respiratory Failure in Interstitial Lung Diseases: Overview and Clinical Insights.

Authors:  Paola Faverio; Federica De Giacomi; Giulia Bonaiti; Anna Stainer; Luca Sardella; Giulia Pellegrino; Giuseppe Francesco Sferrazza Papa; Francesco Bini; Bruno Dino Bodini; Mauro Carone; Sara Annoni; Grazia Messinesi; Alberto Pesci
Journal:  Int J Med Sci       Date:  2019-06-10       Impact factor: 3.738

4.  Systemic Lupus Erythematosus Is Associated With a High Risk of Venous Thromboembolism in Hospitalized Patients Leading to Poor Outcomes and a Higher Cost: Results From Nationwide Inpatient Sample Database 2003-2011.

Authors:  Shweta Kishore; Shraddha Jatwani; Bharat Malhotra; Seth T Lirette; Varun Mittal; Vikas Majithia
Journal:  ACR Open Rheumatol       Date:  2019-05-13

5.  Outcomes of patients hospitalized for acute pulmonary embolism by obstructive sleep apnea status.

Authors:  Aditya A Joshi; Raef H Hajjali; Avantee V Gokhale; Triston Smith; Amit K Dey; Garima Dahiya; Joseph B Lerman; Aparna P Sajja; Manreet Kanwar; Amresh Raina
Journal:  Pulm Circ       Date:  2021-03-27       Impact factor: 3.017

Review 6.  Cardiovascular Disease-Associated Skin Conditions.

Authors:  Lia Hojman; Claudio Karsulovic
Journal:  Vasc Health Risk Manag       Date:  2022-02-16

Review 7.  A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.

Authors:  Thomas Bieber; Eugen Feist; Alan D Irvine; Masayoshi Harigai; Ewa Haladyj; Susan Ball; Walter Deberdt; Maher Issa; Susanne Grond; Peter C Taylor
Journal:  Adv Ther       Date:  2022-09-05       Impact factor: 4.070

Review 8.  The Burden of Living With Cutaneous Lupus Erythematosus.

Authors:  Cristina Drenkard; Kamil E Barbour; Kurt J Greenlund; S Sam Lim
Journal:  Front Med (Lausanne)       Date:  2022-08-08

9.  Epidemiology and Genetics of Venous Thromboembolism and Chronic Venous Disease.

Authors:  Richard A Baylis; Nicholas L Smith; Derek Klarin; Eri Fukaya
Journal:  Circ Res       Date:  2021-06-10       Impact factor: 23.213

10.  Venous thrombotic events in psoriasis patients: a systematic review with meta-analysis.

Authors:  Tom Hillary; Jolien Clijmans; Séverine Vermeire; Jo Lambert; Marjan Garmyn; Maya Imbrechts; Thomas Vanassche
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.